Skip to main content
. 2020 Oct 9;59(50):22494–22499. doi: 10.1002/anie.202006725

Figure 4.

Figure 4

A. Synthesized proof of concept HDAC degrader 4 and inhibitory activities against HDAC1, 2, 3, 6, and 8. B. HPLC‐chromatogram of the test cleavage of crude proof of concept PROTAC 4 (cleavage mix: 5 % TFA in CH2Cl2, 1 h, r.t.). C. Immunoblot analysis of cell lysate after HL‐60 cells were treated with 4 at various concentrations (0.1 μM, 1 μM and 10 μM).